DMT-2'-F-dC(Ac)-CE Phosphoramidite

N4-acetyl-5'-O-(4, 4'-dimethoxytrityl)-2'-fluoro-2'-deoxycytidine-3'-CE-Phosphoramidite
Catalog No. PD3-001
CAS No. 159414-99-0
Purity HPLC≥98.0%
Molecular Formula C41H49FN5O8P
Molecular Weight 789.83
Storage Condition -20℃

DMT-2'-F-dC(Ac)-CE Phosphoramidite

N4-acetyl-5'-O-(4, 4'-dimethoxytrityl)-2'-fluoro-2'-deoxycytidine-3'-CE-Phosphoramidite
Grade
Amount/Package: 0.25g / 30mL screwed bottle-28
SKU: PD3-001-025A  |  suitable for  MerMade
Collections:  2'-Fluoro Phosphoramidites Diagnostics Oligo Synthesis Phosphoramidites Phosphoramidites for Diagnostics Recommended Products Synthesis Blocks
Unit price:
$26.00

Price

$26.00
Shipping calculated at checkout.
This variant is unavailable. Contact us if you have particular requirements.
Checkout

This variant only support customization. Click the Inquiry button below to submit your custom request to us.

Price/Order Inquiry

Shipping notes
Products on this site:
Currently ship to United States & Canada.
For shipping worldwide, please contact us.
Processment: within 2 business days, if available.
US: 2-8 days (from CA by FedEx).
Canada: 5-10 days (excludes customs delays).

Related Products

Details

DMT-2’-F-dC(Ac)-CE-Phosphoramidite is a 2'-fluoro (2'-F) phosphoramidite monomer used for solid-phase oligonucleotide synthesis.

It contains a 2'-F modification on the sugar of deoxycytidine (dC) with acetyl (Ac) base protection, a 5’-dimethoxytrityl (DMT) group for 5'-hydroxyl protection, and a cyanoethyl (CE) protecting group on phosphite.

Synthesis of RNA oligonucleotides using 2'-F phosphoramidite increases the nuclease resistance and binding affinity of duplexes formed with complementary sequences.

Applications

Therapeutic oligonucleotides

Commonly used in chemically modified small interfering RNA (siRNA) to enhance stability, potency, and in-vivo performance.[1][2]

Probing and diagnostics

For constructing nuclease-resistant and high-affinity probes (e.g, aptamers) to study biomolecule interactions,[3][4] which can be related to diseases and cancers.[5][6]

Features and Benefits

High purity: Manufactured to ≥98% purity with tightly controlled impurity specifications.
Compatibility: Compatible with standard phosphoramidite chemistry and most commercial synthesizers.
Excellent coupling efficiency and yield.

Other Notes

  • Diluent: Anhydrous Acetonitrile.
  • Storage: Store in a dry and inert atmosphere at -20 °C.
  • Coupling: 6 minute coupling time recommended.

Reference

[1] Manoharan, M., Akinc, A., Pandey, R.K., Qin, J., Hadwiger, P., John, M., Mills, K., Charisse, K., Maier, M.A., Nechev, L. and Greene, E.M., 2011. Unique gene‐silencing and structural properties of 2′‐fluoro‐modified siRNAs. Angewandte Chemie, 123(10), pp.2332-2336. [2] Dowler, Thomas, Denis Bergeron, Anna-Lisa Tedeschi, Luc Paquet, Nicolay Ferrari, and Masad J. Damha. "Improvements in siRNA properties mediated by 2′-deoxy-2′-fluoro-β-D-arabinonucleic acid (FANA)." Nucleic acids research 34, no. 6 (2006): 1669-1675. [3] Kratschmer, Christina, and Matthew Levy. "Effect of chemical modifications on aptamer stability in serum." Nucleic acid therapeutics 27, no. 6 (2017): 335-344. [4] Hervas-Stubbs, Sandra, Mario M. Soldevilla, Helena Villanueva, Uxua Mancheño, Maurizio Bendandi, and Fernando Pastor. "Identification of TIM3 2′-fluoro oligonucleotide aptamer by HT-SELEX for cancer immunotherapy." Oncotarget 7, no. 4 (2015): 4522. [5] Gruenke, Paige R., Khalid K. Alam, Kamal Singh, and Donald H. Burke. "2′-fluoro-modified pyrimidines enhance affinity of RNA oligonucleotides to HIV-1 reverse transcriptase." RNA 26, no. 11 (2020): 1667-1679. [6] Lozano, Teresa, Mario Martínez Soldevilla, Noelia Casares, Helena Villanueva, Maurizio Bendandi, Juan Jose Lasarte, and Fernando Pastor. "Targeting inhibition of Foxp3 by a CD28 2′-Fluro oligonucleotide aptamer conjugated to P60-peptide enhances active cancer immunotherapy." Biomaterials 91 (2016): 73-80.

Specifications
  • Catalog No.
    PD3-001
  • CAS No.
    159414-99-0
  • SMILES
    F[C@@H]1[C@H](OP(OCCC#N)N(C(C)C)C(C)C)[C@@H](COC(C2=CC=C(OC)C=C2)(C3=CC=CC=C3)C4=CC=C(OC)C=C4)O[C@H]1N5C(N=C(NC(C)=O)C=C5)=O
  • Molecular Formula
    C41H49FN5O8P
  • Molecular Weight
    789.83
  • Appearance
    White powder
  • Purity
    HPLC≥98.0%
  • Storage Condition
    -20℃
  • Moisture Content
    K.F.≤0.20% w/w

Documentation
COA Contact Us

DMT-2’-F-dC(Ac)-CE-Phosphoramidite is a 2'-fluoro (2'-F) phosphoramidite monomer used for solid-phase oligonucleotide synthesis.

It contains a 2'-F modification on the sugar of deoxycytidine (dC) with acetyl (Ac) base protection, a 5’-dimethoxytrityl (DMT) group for 5'-hydroxyl protection, and a cyanoethyl (CE) protecting group on phosphite.

Synthesis of RNA oligonucleotides using 2'-F phosphoramidite increases the nuclease resistance and binding affinity of duplexes formed with complementary sequences.

Applications

Therapeutic oligonucleotides

Commonly used in chemically modified small interfering RNA (siRNA) to enhance stability, potency, and in-vivo performance.[1][2]

Probing and diagnostics

For constructing nuclease-resistant and high-affinity probes (e.g, aptamers) to study biomolecule interactions,[3][4] which can be related to diseases and cancers.[5][6]

Features and Benefits

High purity: Manufactured to ≥98% purity with tightly controlled impurity specifications.
Compatibility: Compatible with standard phosphoramidite chemistry and most commercial synthesizers.
Excellent coupling efficiency and yield.

Other Notes

  • Diluent: Anhydrous Acetonitrile.
  • Storage: Store in a dry and inert atmosphere at -20 °C.
  • Coupling: 6 minute coupling time recommended.

Reference

[1] Manoharan, M., Akinc, A., Pandey, R.K., Qin, J., Hadwiger, P., John, M., Mills, K., Charisse, K., Maier, M.A., Nechev, L. and Greene, E.M., 2011. Unique gene‐silencing and structural properties of 2′‐fluoro‐modified siRNAs. Angewandte Chemie, 123(10), pp.2332-2336. [2] Dowler, Thomas, Denis Bergeron, Anna-Lisa Tedeschi, Luc Paquet, Nicolay Ferrari, and Masad J. Damha. "Improvements in siRNA properties mediated by 2′-deoxy-2′-fluoro-β-D-arabinonucleic acid (FANA)." Nucleic acids research 34, no. 6 (2006): 1669-1675. [3] Kratschmer, Christina, and Matthew Levy. "Effect of chemical modifications on aptamer stability in serum." Nucleic acid therapeutics 27, no. 6 (2017): 335-344. [4] Hervas-Stubbs, Sandra, Mario M. Soldevilla, Helena Villanueva, Uxua Mancheño, Maurizio Bendandi, and Fernando Pastor. "Identification of TIM3 2′-fluoro oligonucleotide aptamer by HT-SELEX for cancer immunotherapy." Oncotarget 7, no. 4 (2015): 4522. [5] Gruenke, Paige R., Khalid K. Alam, Kamal Singh, and Donald H. Burke. "2′-fluoro-modified pyrimidines enhance affinity of RNA oligonucleotides to HIV-1 reverse transcriptase." RNA 26, no. 11 (2020): 1667-1679. [6] Lozano, Teresa, Mario Martínez Soldevilla, Noelia Casares, Helena Villanueva, Maurizio Bendandi, Juan Jose Lasarte, and Fernando Pastor. "Targeting inhibition of Foxp3 by a CD28 2′-Fluro oligonucleotide aptamer conjugated to P60-peptide enhances active cancer immunotherapy." Biomaterials 91 (2016): 73-80.

Why choose Hongene?

Trusted Partner in Nucleic Acid

Integrated Supply & Commercial Scale

With 26+ years of expertise, we control a secure supply chain for RNA raw materials and provide reliable GMP-grade oligo synthesis from research to commercial kilogram-scale production.

Proprietary Technology & IP

Our proprietary Chemoenzymatic Ligation Platform combines chemical andenzymatic methods, enabling high-putity, cost-effective, and large-scale production of RNA-based therapeutics.

Rigorous Quality

We implement multiple stringent QC steps, maintain ISO certifications, and ensure >99% batch-to-batch consistency, reducing scale-up and PPQ risks.

Manufacturing Scalability

Hongene operates 1.67 million sq. ft Oligonucleotide Manufacturing Facility, with advanced equipments including multiple OligoPilot™ and OligoProcess™ synthesizers (10-1800 mmol). 48 flexible production lines enable one-stop seamless scaling-up of API production from gram-level to tons and acheive high purity of 98%, meeting NMPA, FDA, and EMA standards.

Global Business Network

Our products and services reach over 40 countries and regions, supporting around 3,000 clients worldwide.

Global Business Distribution
40+
Countries & Regions
3000≈
Global Clients
54000+L
Annual NTP Production
58+t
Annual Amidites Production

Ask us anything!

Back to top

My Wishlist